Jill Detmer is a prominent inventor based in Kensington, CA (US). She has made significant contributions to the field of biotechnology, particularly in the detection of genetic mutations associated with cancer. With a total of 5 patents to her name, her work has the potential to impact cancer diagnostics and treatment.

Latest Patents

One of Jill Detmer's latest patents focuses on "Oligonucleotides and methods for detecting KRAS and PIK3CA mutations." This invention provides oligonucleotides capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, these primers enhance the detection of KRAS codon 12, 13, and 61, as well as PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. Additionally, the oligonucleotides can prevent pseudogene amplification when hybridized as reverse primers or detection probes to the mismatch sequences.

Career Highlights

Jill Detmer is currently employed at Siemens Healthcare Diagnostics GmbH, where she continues to innovate in the field of healthcare technology. Her work is instrumental in advancing diagnostic methods that can lead to better patient outcomes.

Collaborations

Some of her notable coworkers include Arejas Uzgiris and Andy Ying, who contribute to the collaborative environment that fosters innovation at Siemens Healthcare Diagnostics GmbH.

Conclusion

Jill Detmer's contributions to biotechnology and cancer diagnostics exemplify the impact of innovative thinking in healthcare. Her patents not only enhance detection methods but also pave the way for improved patient care.

This text is generated by artificial intelligence and may not be accurate.